Clicky

Cocrystal Pharma, Inc.(COCP)

Description: Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.


Keywords: Medicine Biotechnology Biology Influenza Biocides Microbiology Viruses Virus Antiviral Drug Coronavirus HCV Pharmaceuticals Industries Opko Health Influenza Viruses

Home Page: www.cocrystalpharma.com

COCP Technical Analysis

19805 North Creek Parkway
Bothell, WA 98011
United States
Phone: 786 459 1831


Officers

Name Title
Dr. Roger D. Kornberg Ph.D. Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Sam Lee Ph.D. Co-Founder, Interim Co-CEO & Pres
Mr. James J. Martin CPA, CPA, M.B.A., MBA Interim Co-CEO, CFO & Corp. Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4525
Price-to-Sales TTM: 92.4548
IPO Date: 2011-05-19
Fiscal Year End: December
Full Time Employees: 13
Back to stocks